vap
nosocomi
infect
lung
tissu
develop
hour
intub
mechan
ventil
patient
critic
ill
ventil
patient
suscept
pneumonia
due
impair
immun
system
breakdown
anatom
barrier
protect
lower
respiratori
tract
risk
acquir
vap
increas
older
age
year
histori
smoke
alcohol
prolong
stay
icu
chronic
comorbid
condit
diabet
chronic
obstruct
pulmonari
diseas
mani
etiolog
agent
vap
earlyonset
vap
less
day
mechan
ventil
usual
caus
haemophilu
influenza
streptococcu
pneumonia
staphylococcu
aureu
methicillinsensit
lateonset
vap
day
mechan
ventil
usual
caus
pseudomona
aeruginosa
acinetobact
speci
methicillinresist
aureu
mrsa
multidrugresist
gramneg
bacilli
clinic
sign
symptom
vap
includ
presenc
new
onset
fever
increas
product
cough
sputum
leukocytosi
worsen
ga
exchang
new
pulmonari
infiltr
chest
radiograph
invas
diagnosi
bronchoalveolar
lavag
gener
recommend
make
definit
diagnosi
manag
vap
advanc
practic
provid
app
direct
initi
antibiot
therapi
organ
known
frequent
caus
pneumonia
icu
obtain
sputum
blood
cultur
initi
appropri
empir
broadspectrum
without
delay
therapeut
choic
includ
combin
ceftazidim
ciprofloxacin
cover
p
aeruginosa
carbapenem
imipenemcilastatin
cover
extendedspectrum
blactamas
esbl
produc
pathogen
klebsiella
speci
icu
high
preval
mrsa
vancomycin
use
manag
infect
icu
challeng
due
rise
multidrugresist
organ
box
among
problemat
pathogen
follow
esblproduc
enterobacteriacea
klebsiella
speci
escherichia
coli
may
resist
penicillin
cephalosporin
esblproduc
organ
carbapenem
imipenem
meropenem
drug
choic
p
aeruginosa
one
lead
caus
morbid
icu
patient
especi
vap
also
common
caus
icu
infect
associ
devic
cathet
infect
urinari
tract
surgic
site
infect
increas
rate
multidrug
resist
note
especi
immunocompromis
host
box
patient
prolong
hospit
stay
patient
invas
devic
mechan
ventil
patient
prior
prolong
antibiot
use
risk
factor
acquir
pseudomon
infect
age
comorbid
icu
admiss
anemia
burn
andor
invas
devic
treatment
problemat
multidrugresist
pseudomona
current
treatment
option
includ
follow
combin
ceftolozanetazobactam
ceftazidimeavibactam
piperacillintazobactam
cefepim
ceftazidim
carbapenem
plu
addit
agent
colistin
fosfomycin
aminoglycosid
quinolon
app
work
icu
optim
dose
frequenc
longer
infus
time
good
practic
combin
timedepend
antibiot
includ
piperacillintazobactam
cefepim
imipenem
concentrationdepend
antibiot
ciprofloxacin
levofloxacin
acinetobact
baumannii
also
major
caus
vap
bloodstream
infect
risk
factor
includ
longer
icu
stay
recent
surgeri
mechan
ventil
prior
antibiot
exposur
data
nation
nosocomi
infect
surveil
system
indic
resist
acinetobact
speci
rise
treatment
suscept
isol
acinetobact
app
use
broadspectrum
cephalosporin
blactamblactamas
inhibitor
combin
carbapenem
box
antimicrobi
resist
optim
antibiot
use
icu
preval
multidrugresist
organ
increas
icu
lead
increas
mortal
longer
hospit
stay
higher
cost
emerg
resist
among
gramneg
bacteria
signific
implic
mani
therapeut
option
encount
resist
pathogen
includ
mrsa
vancomycinresist
enterococcu
enterobacteriacea
esbl
p
aeruginosa
resist
imipenem
fluoroquinolon
featur
optim
antibiot
therapi
icu
principl
govern
antimicrobi
therapi
icu
includ
ensur
adequaci
initi
empir
therapi
time
rapid
initi
empir
broad
empir
broad
antibiot
sourcetarget
tissuetarget
therapi
eg
lung
urinari
tract
cathet
abdomen
narrow
antimicrobi
choic
base
microbiolog
epidemiolog
data
consid
host
factor
immunosuppress
comorbid
initi
patient
respons
guid
need
work
antibiot
durat
treat
shortest
effect
durat
avoid
unnecessari
combin
therapi
multidrugresist
acinetobact
isol
app
use
polymyxin
colistin
minocyclin
tigecyclin
critic
ill
immunocompromis
patient
increas
risk
communityacquir
opportunist
nosocomi
infect
immunocompromis
host
includ
patient
neutropenia
hematolog
malign
patient
corticosteroid
form
immunosuppress
therapi
solid
transplant
patient
patient
hematopoiet
stem
transplant
hivaid
asplenia
patient
biolog
agent
tumor
necrosi
factor
l
attenu
inflammatori
respons
patient
make
difficult
make
earli
diagnosi
clinic
sign
symptom
frequent
atyp
nonspecif
patient
alway
put
variou
prophylact
antimicrobi
multipl
hospit
also
increas
risk
multidrugresist
organ
infect
immunocompromis
patient
present
hierarch
pattern
depend
level
immunosuppress
neutropenia
count
morbid
mortal
high
earli
empir
antimicrobi
therapi
univers
indic
bacteri
pneumonia
bacteremia
gastrointestin
gi
central
nervou
system
infect
occur
high
frequenc
hivaid
patient
depend
level
common
pathogen
includ
mycobacterium
tuberculosi
pneumocysti
p
aeruginosa
endem
mycos
candida
speci
histoplasma
capsulatum
coccidioid
speci
toxoplasma
gondii
listeria
monocytogen
pathogen
frequent
encount
level
less
includ
mycobacterium
avium
complex
cryptococcu
neoforman
cmv
herp
simplex
viru
hsv
varicellazost
viru
vzv
although
advent
antiretrovir
therapi
reduc
incid
pathogen
aureu
streptococcu
pneumonia
haemophilu
influenza
common
fatal
bacteri
infect
patient
irrespect
level
diarrhea
hivaid
patient
often
caus
protozoa
cryptosporidium
parvum
immun
reconstitut
inflammatori
syndrom
lifethreaten
complic
antiretrovir
therapi
may
occur
lead
exuber
inflammatori
respons
pathogen
may
previous
latent
gramposit
organ
rise
neutropenia
patient
includ
staphylococcu
streptococcu
enterococcu
corynebacterium
speci
gramneg
bacilli
includ
pseudomona
escherichia
klebsiella
speci
empir
therapi
cover
gramneg
gramposit
organ
recommend
febril
neutropen
patient
patient
undergon
solid
organ
transplant
present
broad
spectrum
infect
overtim
postop
period
common
infect
includ
health
careassoci
pneumonia
urinari
tract
infect
catheterassoci
deviceassoci
infect
risk
opportunist
infect
increas
time
due
immunosuppress
therapi
prevent
organ
reject
virus
increasingli
recogn
major
caus
morbid
icu
tabl
show
commonli
encount
speci
clinic
featur
workup
manag
prevent
icu
viral
ill
commun
acquir
nosocomi
virus
lead
multipl
organ
system
complic
commonli
affect
system
respiratori
gi
neurolog
system
skin
mucou
membran
eventu
may
lead
sepsi
viral
infect
also
major
sourc
morbid
neonat
icu
box
also
lead
caus
central
nervou
system
infect
box
prompt
diagnosi
antivir
therapi
key
good
outcom
longterm
populationwid
prevent
immun
prophylaxi
infect
control
routin
encourag
viral
communityacquir
pneumonia
frequent
caus
influenza
follow
respiratori
virus
parainfluenza
rhinoviru
adenoviru
rsv
coronavirus
symptom
viral
pneumonia
may
vari
fever
myalgia
arthralgia
headach
short
breath
cough
acut
respiratori
distress
syndrom
app
work
icu
need
recogn
viral
communityacquir
pneumonia
earli
manag
aggress
prevent
complic
improv
outcom
diagnosi
made
clinic
confirm
serolog
polymeras
chain
reaction
pcr
cultur
treatment
mostli
support
caus
agent
influenza
oseltamivir
therapi
recommend
adult
patient
shorten
durat
symptom
improv
outcom
sever
case
vaccin
best
prevent
measur
virus
nosocomi
viral
pneumonia
icu
frequent
caus
herpesvirida
famili
virus
includ
hsv
cytomegaloviru
cmv
immunocompromis
patient
particularli
high
risk
see
box
hsv
detect
throat
common
nosocomi
bacteri
speci
among
neonat
staphylococcu
enterococci
enterobact
e
coli
group
b
streptococcu
bloodstream
among
frequent
site
nosocomi
infect
follow
nosocomi
pneumonia
gi
eye
ear
nose
throat
site
major
risk
factor
poor
umbil
handl
central
intraven
cathet
use
outbreak
viral
infect
neonat
icu
commonli
caus
rotaviru
rsv
enteroviru
hepat
viru
adenoviru
nosocomi
infect
transmit
via
droplet
spread
hand
infect
hospit
personnel
individu
contamin
medic
equip
breast
milk
infect
mother
pathogen
hiv
hepat
bc
hsv
vzv
cmv
transmit
vertic
infect
mother
clinic
manifest
sever
requir
mechan
ventil
complic
associ
nosocomi
viral
infect
group
respiratori
complic
rsv
influenza
parainfluenza
adenovirus
coronavirus
gi
complic
rotaviru
common
gi
viru
infant
system
diseas
enteroviru
parechoviru
critic
ill
patient
central
nervou
infect
mening
enceph
caus
signific
morbid
mortal
diagnos
earli
treat
promptli
bacteri
infect
lead
mening
brain
abscess
subdur
empyema
sepsi
viral
infect
also
caus
mening
enceph
optic
neuriti
poliomyel
mening
character
inflamm
mening
surround
brain
spinal
cord
triad
fever
nuchal
rigid
alter
mental
statu
patient
cranial
nerv
palsi
nausea
vomit
headach
photophobia
enceph
inflamm
within
brain
parenchyma
clinic
present
variabl
depend
brain
cell
affect
patient
like
present
alter
level
conscienc
confus
coma
focal
gener
seizur
suspect
patient
receiv
neuroimag
lumbar
punctur
bacteri
mening
confirm
cerebrospin
fluid
csf
posit
find
bacteri
mening
includ
elev
open
pressur
polymorphonuclear
cell
predomin
decreas
glucos
concentr
elev
protein
concentr
viral
mening
open
pressur
usual
normal
lymphocyt
predomin
csf
glucos
usual
normal
antimicrobi
agent
choic
must
penetr
bloodbrain
barrier
base
patient
age
risk
factor
vancomycin
plu
ceftriaxon
prefer
empir
therapi
ampicillin
ad
initi
empir
therapi
children
immunocompromis
host
elderli
year
patient
viral
enceph
manag
acyclovir
respiratori
secret
pcr
hsv
cmv
respons
treatment
acyclovir
ganciclovir
respect
app
ensur
univers
control
precaut
manag
patient
patient
icu
prone
infect
like
develop
multidrugresist
organ
poor
outcom
multidrug
resist
increas
mortal
length
stay
larg
respons
escal
health
care
cost
unit
state
clinic
manifest
bacteri
viral
infect
highli
variabl
icu
patient
rang
sever
respiratori
diseas
sepsi
box
earli
recognit
empir
therapi
recommend
app
must
use
antibiot
wise
icu
app
use
appropri
initi
empir
therapi
deescal
cultur
box
deal
sepsi
system
inflammatori
respons
syndrom
icu
sepsi
system
inflammatori
respons
syndrom
result
infect
sepsi
describ
sever
patient
develop
endorgan
dysfunct
hypotens
respons
fluid
resuscit
spectrum
sepsi
caus
pathogen
rapidli
chang
predominantli
gramneg
organ
gramposit
organ
hemodynam
tissu
perfus
chang
septic
patient
may
includ
arteri
hypotens
hyperlactatemia
mmoll
decreas
capillari
refil
sepsi
suspect
clinician
rapidli
administ
broadspectrum
antibiot
surviv
sepsi
campaign
bundl
recommend
follow
measur
monitor
lactat
level
obtain
blood
cultur
prior
administr
antibiot
begin
rapid
administr
crystalloid
manag
hypotens
elev
lactat
mmoll
appli
vasopressor
patient
hypotens
fluid
resuscit
maintain
mean
arteri
pressur
mm
hg
manag
sepsi
patient
involv
lot
support
care
first
hour
dedic
restor
adequ
perfus
provid
antibiot
optim
oxygen
suppli
demand
suscept
data
avail
emerg
reemerg
infecti
pathogen
well
drug
resist
involv
enterobacteriacea
speci
acinetobact
baumannii
pseudomona
consid
major
threat
public
health
need
develop
new
effect
drug
vaccin
effect
infect
control
practic
emphas
global
